Mishima Gerhart
General Counsel en PLIANT THERAPEUTICS, INC. .
Perfil
Mishima Gerhart is currently the Chief Regulatory Officer at Pliant Therapeutics, Inc. Prior to this, Mishima held positions as the Head-Regulatory Affairs at Genzyme Corp.
from 2014 to 2016, and as the Head-Global Regulatory Affairs at Sanofi from 2016 to 2020.
Mishima also served as the Chief Regulatory Officer & Head-Quality at Taysha Gene Therapies, Inc. Mishima's education includes an undergraduate degree from Kutztown University of Pennsylvania and a graduate degree from Temple University (Pennsylvania).
Cargos activos de Mishima Gerhart
| Empresas | Cargo | Inicio |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | General Counsel | 16/10/2023 |
Antiguos cargos conocidos de Mishima Gerhart.
| Empresas | Cargo | Fin |
|---|---|---|
| SANOFI | General Counsel | 01/06/2020 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01/01/2016 |
| TAYSHA GENE THERAPIES, INC. | General Counsel | - |
Formación de Mishima Gerhart.
| Kutztown University of Pennsylvania | Undergraduate Degree |
| Temple University (Pennsylvania) | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| SANOFI | Commercial Services |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Mishima Gerhart
